Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SSY Group ( (HK:2005) ) has provided an announcement.
SSY Group Limited has secured approval from China’s National Medical Products Administration for the production and registration of its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical drug that has passed consistency evaluation. The newly approved compound preparation targets adult patients whose hypertension is not adequately controlled by single-drug therapy or who are already stabilized on a similar dual regimen, potentially strengthening SSY Group’s cardiovascular portfolio and supporting its positioning in China’s competitive prescription drug market by broadening its offerings in chronic disease management.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a pharmaceutical company engaged in the development, production and registration of chemical drugs, with a focus on treatments for conditions such as hypertension in the Chinese healthcare market.
YTD Price Performance: 1.06%
Average Trading Volume: 7,525,940
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.44B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.